GoHealth Yönetim
Yönetim kriter kontrolleri 1/4
Şu anda CEO hakkında yeterli bilgiye sahip değiliz.
Anahtar bilgiler
Vijay Kotte
İcra Kurulu Başkanı
US$13.8m
Toplam tazminat
| CEO maaş yüzdesi | 7.05% |
| CEO görev süresi | 4yrs |
| CEO sahipliği | 5.7% |
| Yönetim ortalama görev süresi | 3.2yrs |
| Yönetim Kurulu ortalama görev süresi | less than a year |
Son yönetim güncellemeleri
Recent updates
Anlatı Güncellemesi • Jun 01
GOCO: Higher Growth Assumptions Will Support Upside Despite Nasdaq Listing Risk
Analysts have adjusted their price target on GoHealth from $4.70 to $5.13, citing updated assumptions for revenue growth, profit margins, discount rate, and future P/E following recent research, including a downgrade at Freedom Broker. What's in the News GoHealth reported that it will be unable to file its next 10-Q with the SEC by the required deadline, citing a delayed SEC filing as of May 18, 2026.
Anlatı Güncellemesi • Apr 30
GOCO: Lower P E And Improved Revenue Outlook Will Support Returns
Analysts have cut their 12 month price target for GoHealth by about $3, reflecting a reset in fair value assumptions along with updated views on revenue growth, margins and future P/E, following a recent downgrade highlighted in Street research. Analyst Commentary Bearish analysts are framing the latest downgrade as part of a broader reset in expectations for GoHealth, with the lower 12 month price target seen as a response to questions about how quickly the business can translate its model into consistent, scalable earnings.Anlatı Güncellemesi • Apr 14
GOCO: Lower Earnings Multiple Will Support Upside Despite Nasdaq Compliance Risk
Analysts cut their GoHealth price target from $7.70 to $4.70 as they factor in updated assumptions for revenue growth and margins, and incorporate the recent downgrade at Freedom Broker into their outlook. Analyst Commentary Bullish Takeaways Bullish analysts view the reset to a US$4.70 target as a cleaner entry point that better reflects current expectations for revenue growth and margins, which they see as more achievable under updated assumptions.Anlatı Güncellemesi • Mar 31
GOCO: Discount Rate Tweaks Will Support Upside Despite Nasdaq Compliance Risk
Analysts have nudged up their price target on GoHealth to $7.70, citing a slightly lower discount rate and modest tweaks to long term revenue growth, profit margin, and future P/E assumptions as key drivers of the change. What's in the News On March 18, 2026, GoHealth received a notice from Nasdaq that it is not in compliance with the minimum US$35 million market value of listed securities requirement under Listing Rule 5550(b)(2) (Nasdaq filing).Anlatı Güncellemesi • Mar 17
GOCO: Stable Assumptions And Low Future P E Will Support Returns
Analysts have kept their GoHealth price target unchanged at $4.50. They point to only slight tweaks in revenue growth, profit margin and forward P/E assumptions that do not materially alter their overall view of the stock.Anlatı Güncellemesi • Mar 03
GOCO: Stronger Margins And Lower P E Will Support Future Cash Flow
Analysts have trimmed their price target on GoHealth to reflect slightly weaker revenue expectations, a modestly stronger profit margin, and a marginally lower forward P/E. This results in a small downward adjustment in their $ price outlook for the stock.Anlatı Güncellemesi • Feb 17
GOCO: Carrier Relationship Reset Will Support Future Cash Flow Recovery
Analysts have sharply reduced GoHealth's target, with one firm lowering its price target to $5 from $12 after Q3 results came in below expectations because of topline weakness tied to a suspended relationship with a large carrier. Analyst Commentary Bearish analysts are recalibrating their expectations after Q3 results came in well below what they were looking for, and the cut in the price target to $5 from $12 signals a more cautious stance on the stock.Anlatı Güncellemesi • Feb 03
GOCO: Cash Burn Discipline And Carrier Reset Could Support Future Upside
Analysts have cut their price targets on GoHealth, including a reduction to US$5 from US$12. They cited weaker than expected Q3 results tied to topline softness from a suspended carrier relationship, a pullback in new enrollment growth, and ongoing concerns about market headwinds and cash flow sustainability.Anlatı Güncellemesi • Jan 20
GOCO: Cash Discipline And Carrier Reset Will Support Future Cash Flow
Analysts have sharply reduced their GoHealth price targets, with one moving from US$12 to US$5. This reflects weaker Q3 results tied to a suspended carrier relationship, as well as concerns about ongoing market headwinds and cash flow visibility.Anlatı Güncellemesi • Jan 06
GOCO: Focus On Cash Burn Discipline And Carrier Reset Supporting Future Stability
Narrative Update on GoHealth Analysts have cut their 12 month price target for GoHealth to US$5.00 from US$12.00, reflecting weaker Q3 results tied to a suspended relationship with a large carrier, softer revenue and Medicare submissions, a pullback in new enrollment growth, and concerns around ongoing market headwinds and uncertainty about achieving sustainable positive cash flow. Analyst Commentary Recent research updates on GoHealth reflect a cautious reset of expectations following Q3 results that came in below prior estimates, with price targets and ratings adjusted to reflect execution risks and a more uncertain growth outlook.Anlatı Güncellemesi • Dec 15
GOCO: Cash Flow Improvements Will Outweigh Carrier Loss And Enrollment Pullback
Analysts have sharply reduced their price target on GoHealth from approximately $12.00 to about $5.00 per share. This reflects weaker than expected Q3 results, revenue headwinds from a suspended carrier relationship, and persistent concerns about the company's ability to deliver sustainable growth and cash flow in a challenging market.Anlatı Güncellemesi • Dec 01
GOCO: Focus On Profitability And Cash Burn Reduction Will Drive Future Stability
Analysts have sharply reduced GoHealth's fair value estimate from $14 to $7.70 per share. They cite ongoing market headwinds, weaker-than-expected Q3 results, and challenges in revenue growth as key reasons for the downward revision.Anlatı Güncellemesi • Nov 17
GOCO: Recent Credit Move Will Boost Flexibility Ahead of Enrollment Period
Analysts have revised GoHealth's fair value estimate downward from $17.20 to $14.00. This change is due to updated model assumptions and increased caution surrounding revenue growth following recent company results and financial transactions.Anlatı Güncellemesi • Aug 25
Financial Flexibility And M&A Will Unlock Medicare And Senior Health Potential
GoHealth’s price target has been revised downward to $18.40, primarily reflecting reduced expectations for both future earnings multiples and revenue growth. What's in the News GoHealth has formed a Transformation Committee with new board members to evaluate strategic opportunities, including acquisitions, securitizations, and capital structure options.Anlatı Güncellemesi • Aug 10
Financial Flexibility And M&A Will Unlock Medicare And Senior Health Potential
Despite higher revenue growth forecasts, GoHealth’s future P/E multiple has dropped sharply, indicating reduced investor confidence in earnings quality or sustainability, leading to a lower consensus price target of $19.60. What's in the News GoHealth has formed a Transformation Committee to evaluate acquisitions, financial structure options, securitizations, and other strategic opportunities for value creation.
Yeni Anlatı • Mar 31
Medicare Engagement And Efficiency Will Drive Future Savings
GoHealth's shift to Medicare engagement enhances consumer relations and boosts operational efficiency, lowering costs and improving margins.Seeking Alpha • May 28
GoHealth: Turning The Corner On Operating Cash Flow
Summary GoHealth's shares have continued to drop despite positive developments, presenting an opportunity for investors to build a position over time. The company has shown positive operating cash flow for five consecutive quarters, reflecting a shift towards profitability and cost containment. Although GOCO previously needed to rely on debt funding, it is now deleveraging, and its focus on operating cash flow is a positive sign for investors. Read the full article on Seeking AlphaCEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$294m |
| Dec 31 2025 | US$14m | US$969k | -US$261m |
| Sep 30 2025 | n/a | n/a | -US$203m |
| Jun 30 2025 | n/a | n/a | -US$30m |
| Mar 31 2025 | n/a | n/a | -US$2m |
| Dec 31 2024 | US$6m | US$900k | -US$7m |
| Sep 30 2024 | n/a | n/a | -US$33m |
| Jun 30 2024 | n/a | n/a | -US$64m |
| Mar 31 2024 | n/a | n/a | -US$67m |
| Dec 31 2023 | US$5m | US$900k | -US$67m |
| Sep 30 2023 | n/a | n/a | -US$127m |
| Jun 30 2023 | n/a | n/a | -US$132m |
| Mar 31 2023 | n/a | n/a | -US$146m |
| Dec 31 2022 | US$10m | US$485k | -US$150m |
Tazminat ve Piyasa: Vijay 'nin toplam tazminatı ($USD 13.76M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 642.98K ).
Tazminat ve Kazançlar: Vijay şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.
CEO
Vijay Kotte (48 yo)
4yrs
Görev süresi
US$13,757,255
Tazminat
Mr. Vijay Kumar Kotte serves as Chief Executive Officer & Director of GoHealth, Inc. from June 06, 2022. He served as Executive Vice President, Strategy & Corporate Development and Chief Solutions Officer...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| Co-Founder & Non-Executive Co-Chairman | 6.4yrs | US$150.00k | 0.042% $ 3.5k | |
| Co-Founder & Non-Executive Co-Chairman | 6.4yrs | US$150.00k | 0.11% $ 9.6k | |
| CEO & Director | 4yrs | US$13.76m | 5.69% $ 483.9k | |
| Chief Financial Officer | 1.7yrs | US$2.06m | 0.42% $ 36.0k | |
| Chief Operating Officer | 2.9yrs | US$2.19m | 1.25% $ 106.1k | |
| Chief Technology Officer | 1.6yrs | Veri yok | Veri yok | |
| Vice President of Investor Relations | no data | Veri yok | Veri yok | |
| Chief Legal Officer & Corporate Secretary | 2.3yrs | Veri yok | 0.14% $ 12.1k | |
| Chief Marketing Officer | 3.4yrs | Veri yok | Veri yok | |
| Chief People Officer | 3.4yrs | Veri yok | Veri yok | |
| Chief Distribution Officer | 1.4yrs | Veri yok | Veri yok |
3.2yrs
Ortalama Görev Süresi
48yo
Ortalama Yaş
Deneyimli Yönetim: GOCO 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.2 yıldır).
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| Co-Founder & Non-Executive Co-Chairman | 6.4yrs | US$150.00k | 0.042% $ 3.5k | |
| Co-Founder & Non-Executive Co-Chairman | 6.4yrs | US$150.00k | 0.11% $ 9.6k | |
| CEO & Director | 4yrs | US$13.76m | 5.69% $ 483.9k | |
| Independent Director | 4.1yrs | US$150.00k | 0.58% $ 49.0k | |
| Director | less than a year | US$135.48k | Veri yok | |
| Director | less than a year | Veri yok | Veri yok | |
| Director | less than a year | US$262.74k | Veri yok | |
| Director | less than a year | US$262.74k | Veri yok | |
| Director | less than a year | US$262.74k | Veri yok |
0.8yrs
Ortalama Görev Süresi
56yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: GOCO 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 0.8 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.
Şirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/06/14 04:57 |
| Gün Sonu Hisse Fiyatı | 2026/06/12 00:00 |
| Kazançlar | 2026/03/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
GoHealth, Inc. 15 Bu analistlerden 4, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Steven Valiquette | Barclays |
| Michael Cherny | BofA Global Research |
| Elizabeth Anderson | Evercore ISI |